Pineal and Cortical Melatonin Receptors MT1 and MT2 Are Decreased in Alzheimer's Disease
Overview
Authors
Affiliations
The pineal hormone melatonin is involved in physiological transduction of temporal information from the light dark cycle to circadian and seasonal behavioural rhythms, as well as possessing neuroprotective properties. Melatonin and its receptors MT1 and MT2, which belong to the family of G protein-coupled receptors, are impaired in Alzheimer's disease (AD) with severe consequences to neuropathology and clinical symptoms. The present data provides the first immunohistochemical evidence for the cellular localization of the both melatonin receptors in the human pineal gland and occipital cortex, and demonstrates their alterations in AD. We localized MT1 and MT2 in the pineal gland and occipital cortex of 7 elderly controls and 11 AD patients using immunohistochemistry with peroxidase-staining. In the pineal gland both MT1 and MT2 were localized to pinealocytes, whereas in the cortex both receptors were expressed in some pyramidal and non-pyramidal cells. In patients with AD, parallel to degenerative tissue changes, there was an overall decrease in the intensity of receptors in both brain regions. In line with our previous findings, melatonin receptor expression in AD is impaired in two additional brain areas, and may contribute to disease pathology.
The MT1 receptor as the target of ramelteon neuroprotection in ischemic stroke.
Zhang X, Peng B, Zhang S, Wang J, Yuan X, Peled S J Pineal Res. 2023; 76(1):e12925.
PMID: 37986632 PMC: 10872556. DOI: 10.1111/jpi.12925.
Angelova V, Georgiev B, Pencheva T, Pajeva I, Rangelov M, Todorova N Pharmaceuticals (Basel). 2023; 16(9).
PMID: 37765003 PMC: 10534827. DOI: 10.3390/ph16091194.
Forgham H, Liu L, Zhu J, Javed I, Cai W, Qiao R Coord Chem Rev. 2023; 487.
PMID: 37305445 PMC: 10249757. DOI: 10.1016/j.ccr.2023.215172.
The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.
Hagstrom A, Kal Omar R, Williams P, Stalhammar G BMC Cancer. 2022; 22(1):398.
PMID: 35413810 PMC: 9006630. DOI: 10.1186/s12885-022-09464-w.
Chachaj A, Gasiorowski K, Szuba A, Sieradzki A, Leszek J Curr Neuropharmacol. 2022; 21(2):380-391.
PMID: 35410605 PMC: 10190136. DOI: 10.2174/1570159X20666220411091332.